Mesenchymal Stem Cell

Therapies for ALS

​

Mar 10th 2021 at 4:00 pm PT

​

 

5:00pm MT,     6:00pm CT,     7:00pm ET

​

​

​

Our speaker, Dr. Nathan Staff from Mayo Clinic, will share the

phase 2 study on mesenchymal stem cells derived from patient

adipose (fat) tissue as therapy for ALS.

​

RSVP below to join the event

Dr. Nathan Staff, M.D., Ph.D. 

Neurologist, Mayo Clinic

Dr. Staff is a neurologist at Mayo Clinic in Rochester, Minnesota, and an associate professor of neurology at the Mayo Clinic College of Medicine and Science.

 

His research focus is to discover new treatments or prevent peripheral nervous system damage that occurs after surgery, from chemotherapy and ALS. Dr. Staff's Translational Neuromuscular Disease Research Lab helps accomplish the development of treatments in the laboratory setting and then apply them in clinical trials.

 

Dr. Staff's research team has led studies focused on mesenchymal stem cells (MSCs) in amyotrophic lateral sclerosis (ALS), having completed a Phase I first-in-human study and launched a Phase II study using these cells. Active clinical trials for the Translational Neuromuscular Disease Research Lab include:

​

• Intrathecal Autologous Adipose-Derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)

• Safety and Efficacy of Repeated Administration of NurOwn in ALS Patients

• Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS

​​